# Principles of Surgical Oncology

## Introduction

Surgery remains the primary curative modality for the majority of solid malignancies. The principles of surgical oncology have evolved significantly from the radical resections of Halsted to the modern era of multidisciplinary, biology-driven, and increasingly minimally invasive approaches. General surgery residents must understand the foundational principles of cancer biology, staging, surgical margins, lymph node management, and the integration of surgery with systemic therapy and radiation in the multimodal treatment of cancer.

## Cancer Biology Fundamentals

The hallmarks of cancer, as described by Hanahan and Weinberg, include sustaining proliferative signaling, evading growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, activating invasion and metastasis, deregulating cellular energetics, avoiding immune destruction, genome instability, and tumor-promoting inflammation. Tumor heterogeneity, both intratumoral and intertumoral, drives treatment resistance and disease progression. The metastatic cascade proceeds through local invasion, intravasation, circulation, extravasation, and colonization at distant sites, and the "seed and soil" hypothesis proposed by Paget in 1889 explains organ-specific patterns of metastasis. The tumor microenvironment, comprising stromal cells, immune cells, vasculature, and extracellular matrix, interacts with tumor cells to promote or suppress growth and is critical to understanding immunotherapy approaches. Driver mutations include oncogenes with gain-of-function alterations such as KRAS and HER2, and tumor suppressor genes with loss-of-function alterations such as TP53, APC, and BRCA1/2, all of which govern tumor initiation and progression.

## Staging and Preoperative Assessment

### TNM Staging System (AJCC)

The T component describes the size and local extent of the primary tumor, ranging from Tis (in situ) to T4 (invasion of adjacent structures). The N component classifies regional lymph node involvement by number and location of positive nodes. The M component indicates the presence or absence of distant metastatic disease, designated as M0 or M1. Stage groupings from I through IV combine TNM categories and correlate with prognosis, guiding treatment decisions and allowing comparison of outcomes across institutions.

### Preoperative Workup

Tissue diagnosis through histopathologic confirmation is required before definitive resection in most cases, and core needle biopsy is preferred over fine needle aspiration because it preserves tissue architecture and permits molecular testing. Cross-sectional imaging with CT, MRI, and PET/CT is used for staging, with PET/CT being most useful for detecting occult metastatic disease in lung, esophageal, head and neck, and colorectal cancers. Tumor markers such as CEA for colorectal cancer, CA 19-9 for pancreatic cancer, AFP for hepatocellular carcinoma, and CA-125 for ovarian cancer are useful for monitoring treatment response and recurrence but are not appropriate for screening. Molecular and genomic profiling increasingly guides therapy, with examples including KRAS/BRAF status in colorectal cancer, HER2 amplification in breast and gastric cancer, and microsatellite instability status for immunotherapy eligibility. All cancer patients should be discussed in a multidisciplinary tumor board setting that includes surgical oncology, medical oncology, radiation oncology, radiology, and pathology.

<image>Diagram illustrating the TNM staging system for solid tumors showing progressive T stages from Tis through T4 with increasing depth of invasion, N stages showing regional lymph node involvement patterns, and M0 versus M1 metastatic disease with common distant metastatic sites</image>

## Principles of Surgical Resection

### Margin Assessment

R0 resection denotes microscopically negative margins and is the goal of curative surgery, representing the strongest predictor of long-term survival in most solid tumors. R1 resection indicates microscopically positive margins with tumor at the inked margin, while R2 resection describes macroscopically positive margins with gross residual disease. Appropriate margin width varies by tumor type: pancreatic cancer requires greater than 1 mm, breast cancer follows the "no ink on tumor" standard for invasive disease, soft tissue sarcoma requires 1-2 cm or an intact fascial plane, and melanoma requires 1-2 cm depending on Breslow thickness. Frozen section analysis provides intraoperative pathologic assessment of margins to guide the extent of resection, though it is limited by sampling error and difficulty with certain histologies.

### En Bloc Resection

The principle of en bloc resection requires that the primary tumor, regional lymphatics, and any directly invaded adjacent structures be removed as a single specimen without violation of the tumor capsule or plane. The no-touch technique minimizes manipulation of the tumor during resection to reduce intraoperative tumor cell dissemination, with early ligation of vascular pedicles. In minimally invasive surgery, proper specimen extraction technique, use of specimen bags, and wound protection reduce the risk of port-site and wound recurrence from implantation metastases.

### Lymph Node Management

Sentinel lymph node biopsy identifies the first draining lymph node or nodes using technetium-99m sulfur colloid and/or blue dye or indocyanine green, and is the standard staging procedure for melanoma and breast cancer, sparing patients the morbidity of complete lymphadenectomy when sentinel nodes are negative. Therapeutic lymphadenectomy involves removal of clinically involved nodes, with the extent varying by cancer type, such as D2 lymphadenectomy for gastric cancer and complete mesocolic excision for colon cancer. Minimum lymph node counts for adequate staging include 12 nodes for colon cancer and 15 nodes for gastric cancer, and inadequate lymph node harvest may result in understaging of disease.

## Neoadjuvant and Adjuvant Therapy

### Neoadjuvant Therapy

Neoadjuvant therapy refers to systemic therapy (chemotherapy, targeted therapy, or immunotherapy) and/or radiation given before surgery. Its advantages include downstaging to improve resectability, in vivo assessment of tumor chemosensitivity, early treatment of micrometastatic disease, and the potential for organ preservation. Standard indications include locally advanced rectal cancer treated with chemoradiation, borderline resectable pancreatic cancer, locally advanced breast cancer, esophageal cancer treated with chemoradiation, and an expanding number of tumor types in which neoadjuvant approaches are being adopted for resectable disease. Pathologic complete response, defined as no viable tumor cells in the resected specimen, is strongly associated with improved long-term survival.

### Adjuvant Therapy

Adjuvant therapy is treatment given after surgical resection to eradicate residual micrometastatic disease and reduce the risk of recurrence. Standard indications include stage III colon cancer (FOLFOX), high-risk stage II colon cancer, node-positive breast cancer, resected pancreatic cancer, and selected other solid tumors. Timing is important, as adjuvant therapy should be initiated within 4-8 weeks of surgery and delayed initiation is associated with worse outcomes.

<image>Timeline illustration showing the integration of neoadjuvant therapy, surgical resection, and adjuvant therapy in the multimodal treatment of cancer, with decision points for restaging, margin assessment, pathologic response evaluation, and surveillance planning</image>

## Role of Surgery in Metastatic Disease

Cytoreductive surgery with curative intent is appropriate in selected settings, including hepatic metastasectomy for colorectal liver metastases (which achieves 5-year survival of 40-50% with R0 resection) and pulmonary metastasectomy for selected tumor types such as sarcoma, colorectal cancer, and renal cell carcinoma. Debulking or cytoreductive surgery is performed in ovarian cancer, where optimal debulking to no residual disease improves survival, and in peritoneal carcinomatosis with hyperthermic intraperitoneal chemotherapy (HIPEC) for selected patients with appendiceal, colorectal, or mesothelioma primaries. Palliative surgery provides relief of obstruction, control of hemorrhage, pain management, and improvement of quality of life when curative intent is not possible. Oligometastatic disease is increasingly recognized as a potentially curable state, and combined local therapy (surgery, ablation, or SBRT) with systemic therapy may achieve long-term disease control.

## Surgical Innovations in Oncology

Minimally invasive surgical oncology using laparoscopic and robotic approaches has been shown to be oncologically equivalent to open surgery for colon, rectal, gastric, and lung cancers while offering faster recovery. Organ preservation strategies include the watch-and-wait approach for rectal cancer patients achieving clinical complete response after neoadjuvant chemoradiation, as well as active surveillance for selected early-stage cancers. Ablative techniques such as radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation are used for unresectable hepatic, renal, and pulmonary tumors. Intraoperative radiation therapy delivers a single fraction of radiation directly to the tumor bed during surgery and is used in breast cancer and selected retroperitoneal sarcomas. Fluorescence-guided surgery using indocyanine green and tumor-specific fluorescent probes enables real-time intraoperative margin and lymph node assessment.

## Cancer Screening and Prevention

Hereditary cancer syndromes of importance to the surgeon include Lynch syndrome (hereditary nonpolyposis colorectal cancer), familial adenomatous polyposis, BRCA1/2-associated breast and ovarian cancer, Li-Fraumeni syndrome, and MEN syndromes. Risk-reducing surgery plays a critical role and includes prophylactic mastectomy and salpingo-oophorectomy for BRCA carriers, total proctocolectomy for FAP, and prophylactic thyroidectomy for MEN2/RET mutations. Genetic counseling and testing are essential for patients meeting criteria based on family history, young age at diagnosis, or specific tumor types, and germline testing is increasingly performed on all patients with certain cancers.

## Key Clinical Pearls

R0 resection is the single most important prognostic factor in the surgical treatment of most solid tumors, and margins should never be compromised for a smaller operation. Multidisciplinary tumor board discussion should precede definitive surgical treatment for all cancer patients. Neoadjuvant therapy is increasingly favored because it allows in vivo assessment of tumor biology and may improve resectability and survival. Sentinel lymph node biopsy has replaced routine lymphadenectomy for staging clinically node-negative breast cancer and melanoma. Understanding hereditary cancer syndromes and the role of risk-reducing surgery is essential, and genetic counseling is an integral part of surgical oncology practice.

## References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646-674.
2. Amin MB, Edge SB, Greene FL, et al., eds. *AJCC Cancer Staging Manual*. 8th ed. Springer; 2017.
3. Burt BM, Groth SS, Sada YH, et al. Principles of surgical oncology. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, eds. *Sabiston Textbook of Surgery*. 21st ed. Elsevier; 2022.
4. Mieog JSD, Achterberg FB, Bastiaannet E, et al. Fluorescence-guided surgery in oncology: current status and future directions. *Ann Surg Oncol*. 2022;29(5):3353-3365.